Focused On-demand Library for Fibroblast growth factor 10

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.

The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.

The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.

We utilise our cutting-edge, exclusive workflow to develop focused libraries.

Fig. 1. The sreening workflow of Receptor.AI

Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.

Our library stands out due to several important features:

The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.
Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.
Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.
Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.

partner

Reaxense

upacc

O15520

UPID:

FGF10_HUMAN

Alternative names:

Keratinocyte growth factor 2

Alternative UPACC:

O15520; C7FDY0; Q6FHR3; Q6FHT6; Q96P59

Background:

Fibroblast growth factor 10 (FGF10), also known as Keratinocyte growth factor 2, is pivotal in embryonic development, cell proliferation, and differentiation. It is essential for normal branching morphogenesis, suggesting a significant role in the formation and development of various tissues and organs. FGF10's involvement in wound healing underscores its importance in tissue repair and regeneration.

Therapeutic significance:

FGF10's link to Aplasia of lacrimal and salivary glands and Lacrimo-auriculo-dento-digital syndrome 3 highlights its therapeutic potential. Understanding the role of Fibroblast growth factor 10 could open doors to potential therapeutic strategies for these conditions, emphasizing the need for targeted research into its biological mechanisms and therapeutic applications.